Evidence map›Paper›PMID 35264209›Full record

ArticleJournal of orthopaedic surgery and research2022

Knockdown of CD44 inhibits proliferation, migration and invasion of osteosarcoma cells accompanied by downregulation of cathepsin S.

Lingwei Kong, Hairu Ji, Xintian Gan, Sheng Cao, Zhehong Li, Yu Jin

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. CD44 Modulates Cell Migration and Invasion in Ewing Sarcoma Cells.International journal of molecular sciences · 2023
    Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lingwei KongDepartment of Orthopaedics, The Affiliated Hospital of Chengde Medical College, No. 1 Nanyingzi Street, Chengde, 067000, Hebei, China.
Hairu JiPathology Teaching and Research Section, Chengde Medical College, Chengde, 067000, Hebei, China.
Xintian GanDepartment of Orthopaedics, The Affiliated Hospital of Chengde Medical College, No. 1 Nanyingzi Street, Chengde, 067000, Hebei, China.
Sheng CaoDepartment of Orthopaedics, The Affiliated Hospital of Chengde Medical College, No. 1 Nanyingzi Street, Chengde, 067000, Hebei, China.
Zhehong LiDepartment of Orthopaedics, The Affiliated Hospital of Chengde Medical College, No. 1 Nanyingzi Street, Chengde, 067000, Hebei, China.
Yu JinDepartment of Orthopaedics, The Affiliated Hospital of Chengde Medical College, No. 1 Nanyingzi Street, Chengde, 067000, Hebei, China. 358620793@qq.com.
Affiliated Hospital of Chengde Medical College · CN

Funding

Department of Education of Hebei Province QN2020107Department of Health of Hebei Province 20200352Department of Health of Hebei Province 20200378
6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is a malignant bone tumour of mesenchymal origin. These tumours are characterised by rich vascularisation, therefore promoting rapid proliferation and facilitating metastasis. CD44 has been reported to be involved in OS, but its role and molecular mechanisms in the pathogenesis of the disease are not fully determined.

methodsIn this study, we investigated the antitumor effect of CD44 on the development of OS and further explored the molecular mechanisms. The expression of CD44, cathepsin S and MMP-9 was detected by Western blot (WB) and reverse transcription-polymerase chain reaction (RT-qPCR) in different cell lines (MG63, U2OS OS and hFOB 1.19). To elucidate the role of CD44 in OS, MG63 and U2OS cells were treated with small interference RNA (siRNA) to knock down CD44, and the knockdown efficiency was validated with GFP and RT-qPCR. Furthermore, cell proliferation was assayed using Cell Counting Kit‑8 (CCK-8) and colony formation assays, and cell migration and invasion were assayed by transwell and wound-healing assays.

resultsWe found that CD44 expression in the MG63 and U2OS OS cell lines was markedly increased compared to that of the human osteoblast hFOB 1.19 cell line. Knockdown of CD44 inhibited proliferation, migration and invasion of MG63 and U2OS cells. Cathepsin S expression in the MG63 and U2OS OS cell lines was increased compared to that of the human osteoblast hFOB 1.19 cell line. When CD44 was knocked down, its expression level went down.

conclusionTaken together, our data reinforced the evidence that CD44 knockdown inhibited cell proliferation, migration and invasion of OS cells accompanied by altered expression of cathepsin S. These findings offer new clues for OS development and progression, suggesting CD44 as a potential therapeutic target for OS.

Indexed as

Bone NeoplasmsCathepsinsCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsNeoplasm InvasivenessOsteosarcomacathepsin SCathepsinsCD44 protein, humanHyaluronan ReceptorsCathepsin SCD44InvasionMigrationOsteosarcomaProliferation

Identifiers

PMID35264209
PMCPMC8905747
OpenAlexW4220742446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.